TA新辅助化疗方案治疗局部进展期乳腺癌的有效性和安全性  

Efficacy and safety of TA neoadjuvant chemotherapy in the treatment of locally advanced breast cancer

作　　者：王娅 李孟圈[1] 郑世鹏 Wang Ya;Li Mengquan;Zheng Shipeng(Department of Breast Surgery,the First Affiliated Hospital of Zhengzhou University,Zhengzhou 450001,China)

机构地区：[1]郑州大学第一附属医院乳腺外科一病区,河南郑州450052

出　　处：《河南医学研究》2018年第7期1188-1190,共3页Henan Medical Research

摘　　要：目的探讨TA新辅助化疗方案治疗局部进展期乳腺癌的有效性和安全性。方法选取2015年1月至2016年5月郑州大学第一附属医院乳腺外科一病区收治的64例局部进展期乳腺癌患者,均接受2~4个疗程TA方案新辅助化疗,观察患者治疗效果及不良反应发生情况。结果完全缓解7例,部分缓解44例,病情稳定13例,病情进展0例,有效率为80%。脱发发生率为100%,中性粒细胞减少发生率为90%,恶心呕吐发生率为78%。结论 TA方案是局部进展期乳腺癌患者有效的新辅助化疗方案,安全性高。Objective To analyze the efficacy and safety of TA neoadjuvant chemotherapy（ docetaxel ＋ pirarubicin） in the treatment of locally advanced breast cancer（ LABC）. Methods Sixty-four LABC patients received TA neoadjuvant chemotherapy were included in this retrospective study from January of 2015 to May of 2016. All patients were treated with 2 to 4 cycles TA neoadjuvant chemotherapy. Efficacy and safety of TA neoadjuvant chemotherapy in the treatment of LABC were analyzed. Results Complete response was observed in 7 patients. Partial response was observed in 44 cases. Stable disease was observed in 13 cases. The efficiency was 80%. The main side effect was alopecia（ 100%）. The ccurrence rate of alimentary canal reaction was 90%. The ccurrence rate of bone marrow suppression was 78%.Conclusion The TA scheme is an effective and scure regimen of neoadjuvant chemotherapy for LABC patients.

关 键 词：乳腺癌 新辅助化疗 不良反应 

分 类 号：R655.8[医药卫生—外科学]